We see this everyday
IT WILL GAP DOWN ONCE IT BREAKS 2.90.
Needham analyst Alan Carr set a price target of $15 on the stock, but warned that the company still needs to confirm that the reduction in the rate of viral shedding will mean fewer lesions. That will likely be the main goal of a Phase 3 trials set to start in the second half of next year, and Carr said the lack of a placebo arm complicates the interpretation of the data.
ValuEngine upgrades GENOCEA BIOSCIENCES INC from STRONG SELL to SELL.
BY Investars Analyst Actions - public
— 7:14 AM ET 04/01/2016
On March 31, 2016 ValuEngine upgraded GENOCEA BIOSCIENCES INC ( GNCA
) from STRONG SELL to SELL.
Phase 3 failures are not good....took my loss